Ii like the fact that the new acquisition, Monal Shah to IMU,...

Ii like the fact that the new acquisition, Monal Shah to IMU, formerly of windMIL therapeutics, were focused heavily on solid tumours. An apparent holy grail of medical research companies (financially and medically).

''These unique properties found in bone marrow T cells allow MILs to be grown for any patient, for any tumor type — hematologic or solid. Evidence suggests that MILs (marrow-infiltrating lymphocytes) could be activated to recognize and treat numerous solid tumor cancers, including lung, bladder, breast, glioblastoma, head and neck, melanoma, sarcoma, prostate, renal cell, hepatocellular and others.''

''Imugene focuses on untapped side of immuno-oncology with B cell vaccine''


He is well positioned to jump in seamlessly.....

Just my humble opinion.